Riluzole
- Generic Name
- Riluzole
- Brand Names
- Exservan, Rilutek, Tiglutik, Riluzole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H5F3N2OS
- CAS Number
- 1744-22-5
- Unique Ingredient Identifier
- 7LJ087RS6F
- Background
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
- Indication
For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
- Associated Conditions
- Amyotrophic Lateral Sclerosis (ALS)
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
- Conditions
- Advanced Malignant Solid NeoplasmRecurrent MelanomaRefractory Malignant Solid NeoplasmStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT01303341
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)
- Conditions
- Cervical Spondylotic Myelopathy
- Interventions
- Drug: Placebo medication
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- AOSpine North America Research Network
- Target Recruit Count
- 270
- Registration Number
- NCT01257828
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Louisiana State University, Baton Rouge, Louisiana, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Yale University
- Target Recruit Count
- 104
- Registration Number
- NCT01204918
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Yale University, Yale Depression Research Program, New Haven, Connecticut, United States
🇺🇸Massachussettes General Hospital, Depression Clinical and Research Center, Boston, Massachusetts, United States
Efficacy of Riluzole in Hereditary Cerebellar Ataxia
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- S. Andrea Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01104649
- Locations
- 🇮🇹
Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, II Faculty of Medicine, "Sapienza" University of Rome, Rome, Italy
Riluzole and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
- Conditions
- Metastatic CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Radiation: whole-brain radiation therapy
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 9
- Registration Number
- NCT01018836
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 39
- Registration Number
- NCT01018056
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2013-04-29
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Registration Number
- NCT00903214
Riluzole in Fragile X Syndrome
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 6
- Registration Number
- NCT00895752
- Locations
- 🇺🇸
Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children, Indianapolis, Indiana, United States
Safety of Riluzole in Patients With Acute Spinal Cord Injury
- Conditions
- Spinal Cord Injury
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00876889
- Locations
- 🇺🇸
The University of Texas, Houston, Texas, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸University of Louisville Health Sciences Center, Louisville, Kentucky, United States
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 512
- Registration Number
- NCT00868166
- Locations
- 🇧🇪
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium
🇫🇷Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France
🇫🇷Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.